Alan Wovsaniker Partner

New Jersey
T 973.597.2564 | F 973.597.2565



Alan has more than 35 years of experience handling mergers and acquisitions, securities offerings, corporate finance and governance, securities compliance, financial restructurings, and general corporate matters. A significant portion of Alan’s practice is focused on helping biotechnology companies gain the resources they need to invent, prove, and market new ways to enhance human health.

An “excellent lawyer” (Chambers), Alan provides his clients with comprehensive support across their companies’ life cycle, whether he is acting as day-to-day legal counselor or as a key strategist for raising capital, acquiring assets and capabilities, complying with legal and regulatory requirements, or selling the business. He also helps clients restructure or sell companies that are in bankruptcy.

Representative Engagements

Represented MiaMed, Inc. in its sale to Amicus Therapeutics, Inc. (NASDAQ: FOLD)
Represented Celldex Therapeutics, Inc. in its $200 million public offering in 2015 and $103 million public offering in 2013.
Represented NeoStem, Inc. in connection with over 10 public offerings from 2007 to 2014 raising over $150 million, as well as in various private securities offerings.
View More...

Other Distinctions

  • Chambers USA: America's Leading Lawyers for Business – Featured annually as a top leader since the 2003 inception of the guide.

  • The Best Lawyers in America – Featured in three categories: corporate, mergers & acquisitions, and securities law since 2005.  

  • Super Lawyers – Featured since 2005.

Publications

SEC Expands Use of Confidential IPO Filings
Capital Markets & Securities Client Alert, June 30, 2017
Alan Wovsaniker, John Hogoboom
SEC Issues Statement on Conflict Minerals Rule; Not Much Changes
Capital Markets & Securities Client Alert, April 13, 2017
Peter Ehrenberg, Steven Skolnick, John Hogoboom, Laura Kuntz, Alan Wovsaniker
SEC Shortens Settlement Cycle from T+3 to T+2
Capital Markets & Securities Client Alert, March 23, 2017
Peter Ehrenberg, Steven Skolnick, John Hogoboom, Laura Kuntz, Alan Wovsaniker
View More...

Press Mentions

Lowenstein Sandler represented Metalico, Inc. (NYSE MKT: MEA), one of the nation’s largest scrap metal recyclers, in its execution of the merger agreement for the $102 million all-cash sale to Total Merchant Limited, an investment vehicle formed to seek appropriate opportunities in the United States metals and commodities market. The Lowenstein deal team included Steven M. Skolnick, Alan Wovsaniker, Sam E. KhanNick Samedi and Brian Shemesh. , September 11, 2015
Lowenstein Sandler represented Celldex Therapeutics, Inc. in connection with its $200.1 million public offering of common stock underwritten by Jefferies LLC and Leerink Partners LLC as joint book-running managers, Guggenheim Securities, LLC acting as lead manager, and Oppenheimer, Brean Capital, Cantor Fitzgerald and ROTH Capital Partners as co-managers. Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Celldex’s pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. The Lowenstein team included Anthony O. Pergola, Alan Wovsaniker, Michael J. Lerner, Meredith Prithviraj, Robert J. Paradiso, Michael Amalfe and Eugene Cheval. , March 3, 2015
Lowenstein Sandler represented Celldex Therapeutics in its $191 million (gross) underwritten public offering of common stock, which closed on December 10, 2013. Jefferies LLC and Leerink Swann LLC acted as joint book-running managers of the offering. Guggenheim Securities, Oppenheimer & Co. Inc., Wedbush PacGrow Life Sciences, Brean Capital, LLC, Cantor Fitzgerald & Co. and ROTH Capital Partners acted as co-managers of the offering. The Lowenstein Sandler team was led by Anthony O. PergolaMichael J. Lerner and Alan Wovsaniker, with Meredith Prithviraj, Jared Heady and Robert Paradiso. Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Celldex’s pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body’s immune response. , December 10, 2013

Related Areas

Capital Markets & Securities
Corporate
Corporate Governance & Compliance
Life Sciences
Mergers & Acquisitions
PIPEs, SPACs & Registered Direct Offerings
Transactions & Advisory Group

Education


Harvard Law School ( J.D. , 1977 ) , magna cum laude
Brown University ( A.B. , 1974 ) , magna cum laude, Phi Beta Kappa

Bar Admissions


New Jersey

Affiliations


  • Adjunct Faculty, Rutgers University Law School (1989-1995)
  • Adjunct Faculty, Seton Hall University Law School (1988-1991)
  • District V-C Ethics Committee, Supreme Court (1994-1998)
    • Chair (1997-1998)
  • Essex County Bar Association
    • Trustee (1996-1999)
    • Chair, Corporate Law Committee (1999-2003)
    • Chair, Banking Law Committee (1994-1997)
  • New Jersey State Bar Association
  • American Bar Association